Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday, Wall Street Zen reports.
Several other analysts have also recently weighed in on ABEO. Oppenheimer reiterated an “outperform” rating and issued a $21.00 price target (down from $22.00) on shares of Abeona Therapeutics in a report on Friday, August 14th. Roth Capital began coverage on shares of Abeona Therapeutics in a report on Thursday, September 17th. They issued a “buy” rating and a $17.00 price objective for the company. Cantor Fitzgerald upped their price objective on shares of Abeona Therapeutics from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, September 18th. UBS Group reaffirmed a “buy” rating on shares of Abeona Therapeutics in a research report on Friday, September 25th. Finally, Weiss Ratings lowered shares of Abeona Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, November 10th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $21.00.
Check Out Our Latest Report on Abeona Therapeutics
Abeona Therapeutics Stock Performance
Shares of ABEO stock opened at $2.42 on Friday. The firm has a market cap of $138.30 million, a P/E ratio of -2.26 and a beta of 1.50. Abeona Therapeutics has a fifty-two week low of $2.09 and a fifty-two week high of $7.65. The business’s 50 day moving average price is $4.70 and its 200-day moving average price is $5.39.
Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) last announced its earnings results on Monday, November 9th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.09. The company had revenue of $13.49 million during the quarter, compared to the consensus estimate of $14.82 million. Abeona Therapeutics had a negative return on equity of 44.82% and a negative net margin of 160.30%. As a group, equities analysts predict that Abeona Therapeutics will post -0.97 EPS for the current year.
Insider Activity
In related news, CFO Joseph Vazzano sold 9,191 shares of the stock in a transaction dated Tuesday, September 29th. The shares were sold at an average price of $5.16, for a total value of $47,425.56. Following the completion of the transaction, the chief financial officer directly owned 482,888 shares in the company, valued at $2,491,702.08. This trade represents a 1.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Vishwas Seshadri sold 19,608 shares of Abeona Therapeutics stock in a transaction dated Tuesday, September 29th. The shares were sold at an average price of $5.16, for a total transaction of $101,177.28. Following the transaction, the chief executive officer directly owned 1,286,500 shares of the company’s stock, valued at approximately $6,638,340. This trade represents a 1.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 55,428 shares of company stock worth $296,508. 7.10% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Abeona Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in the business. AIGH Capital Management LLC bought a new stake in shares of Abeona Therapeutics in the 3rd quarter worth approximately $15,225,000. AWM Investment Company Inc. purchased a new stake in shares of Abeona Therapeutics in the 2nd quarter worth approximately $9,184,000. Nan Fung Trinity HK Ltd. grew its stake in shares of Abeona Therapeutics by 336.6% in the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 552,270 shares of the biopharmaceutical company’s stock worth $2,899,000 after buying an additional 425,770 shares during the last quarter. Simplify Asset Management Inc. bought a new position in Abeona Therapeutics during the 3rd quarter valued at approximately $1,451,000. Finally, Bank of New York Mellon Corp bought a new position in Abeona Therapeutics during the 2nd quarter valued at approximately $1,262,000. Institutional investors own 80.56% of the company’s stock.
Abeona Therapeutics News Roundup
Here’s some of the latest news about ABEO:
- Neutral Sentiment: Wall Street Zen raised its rating on ABEO to Hold, a less cautious stance that nevertheless does not signal a Buy recommendation. Abeona Therapeutics Stock Bumped Up to Hold by Wall Street Zen
- Negative Sentiment: HC Wainwright cut its FY2027 EPS estimate to a loss of $0.82 from $0.49 and lowered its estimates for each quarter of 2027, signaling expectations of greater losses than previously forecast. MarketBeat analyst estimates
- Negative Sentiment: A separate report noted falling fair-value expectations as concerns grow about the pace of Zevaskyn’s commercial ramp, a potential headwind to the stock. Abeona Therapeutics Stock Sees Fair Value Falls As Zevaskyn Ramp Concerns Grow
Abeona Therapeutics Company Profile
Abeona Therapeutics, Inc. is a biotechnology company focused on developing cell and gene therapies for serious and rare diseases. Its work includes treatments designed to address the underlying genetic causes of disease. The company’s lead product, ZEVASKYN (prademagene zamikeracel), is an autologous gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, a rare inherited skin disorder. Made from a patient’s skin cells, the therapy uses genetic modification to help cells produce type VII collagen and is applied to wounds.
See Also
- Five stocks we like better than Abeona Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
